AR and posterior cortical atrophy: Most patients with primary PCa will need androgen deprivation therapy (ADT), while patients with CRPC may undergo second-generation hormone therapies, e.g., ABI and ENZI, to further inhibit the AR signalling by preventing androgen biosynthesis or AR translocation to the nucleus.